Fresenius Kabi is expanding its Melrose Park site into a manufacturing campus and will invest approximately $250 million over 10 years. The Melrose Park site manufactures generic, sterile injectable pharmaceuticals used in hospitals and clinics throughout the U.S. The multi-stage expansion is set to break ground in 2017.   Fresenius Kabi specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s U.S. headquarters is based in Lake Zurich, IL, and e...